The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
Open accessAbstract
BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are associated with improved survival in several epithelial cancers. The two chemokines CXCL9 and CXCL10 facilitate chemotactic recruitment of TILs, and their intratumoral accumulation is a conceivable way to improve TIL-dependent immune intervention in cancer. However, the prognostic impact of CXCL9 and CXCL10 in high-grade serous ovarian cancer (HGSC) is largely unknown. METHODS: One hundred and eighty four cases of HGSC were immunohistochemically analyzed for CXCL9, CXCL10. TILs were assessed using CD3, CD56 and FOXP3 staining. Chemokine regulation was investigated using the ovarian cancer cell lines OV-MZ-6 and SKOV-3. RESULTS: High expression of CXCL9 and CXCL10 was associated with an approximately doubled overall survival (n=70, CXCL9: HR 0.41; P=0.006; CXCL10: HR 0.46; P=0.010) which was confirmed in an independent validation set (n=114; CXCL9: HR 0.60; P=0.019; CXCL10: HR 0.52; P=0.005). Expression of CXCR3 ligands significantly correlated with TILs. In human ovarian cancer cell lines the cyclooxygenase (COX) metabolite Prostaglandin E2 was identified as negative regulator of chemokine secretion, whereas COX inhibition by indomethacin significantly upregulated CXCL9 and CXCL10. In contrast, celecoxib, the only COX inhibitor prospectively evaluated for therapy of ovarian cancer, suppressed NF-κB activation and inhibited chemokine release. CONCLUSION: Our results support the notion that CXCL9 and CXCL10 exert tumour-suppressive function by TIL recruitment in human ovarian cancer. COX inhibition by indomethacin, not by celecoxib, may be a promising approach to concomitantly improve immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Wang, D., & DuBois, R. N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2809 · Cited by 1,793
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
CXCR3 ligands: redundant, collaborative and antagonistic functions
Groom, J. R., & Luster, A. D. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.158 · Cited by 1,001
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 813
Targeting cyclooxygenase-2 in human neoplasia
Dannenberg, A. J., & Subbaramaiah, K. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00310-6 · Cited by 446
Natural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands
Wendel, M., Galani, I. E., Suri-Payer, E., & Cerwenka, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1440 · Cited by 378
COX-2 as a target for cancer chemotherapy
Ghosh, N., Chaki, R., Mandal, V., & Mandal, S. C. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70262-0 · Cited by 344
Bronger, H., König, J., Kopplow, K., Steiner, H.-H., Ahmadi, R., Herold-Mende, C., Keppler, D., & Nies, A. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1271 · Cited by 295
Self-citationClarke, B., Tinker, A. V., Lee, C.-H., Subramanian, S., van de Rijn, M., Turbin, D., Kalloger, S., Han, G., Ceballos, K., Cadungog, M. G., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2008.191 · Cited by 280
Expression pattern of S100 calcium-binding proteins in human tumors
Ilg, E. C., Schäfer, B. W., & Heizmann, C. W. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961104)68:3<276::aid-ijc2>3.0.co;2-z · Cited by 231
Gupta, R. A., Tejada, L. V., Tong, B. J., Das, S., Morrow, J. D., Dey, S. K., & DuBois, R. N. (2003) · PubMed · Cited by 220
Kundu, N., & Fulton, A. M. (2002) · PubMed · Cited by 189
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
Casrouge, A., Decalf, J., Ahloulay, M., Lababidi, C., Mansour, H., Vallet-Pichard, A., Mallet, V., Mottez, E., Mapes, J., Fontanet, A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci40594 · Cited by 189
Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian Carcinoma
Denkert, C., Köbel, M., Pest, S., Koch, I., Berger, S., Schwabe, M., Siegert, A., Reles, A., Klosterhalfen, B., & Hauptmann, S. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64912-7 · Cited by 188
Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma
Tomšová, M., Melichar, B., Sedláková, I., & Šteiner, I. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.016 · Cited by 186
Shishodia, S., Koul, D., & Aggarwal, B. B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.2011 · Cited by 185
Monoclonal antibodies for the treatment of cancer
Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 170
Clarke, D. L., Clifford, R. L., Jindarat, S., Proud, D., Pang, L., Belvisi, M., & Knox, A. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.0999952 · Cited by 164
Redjimi, N., Raffin, C., Raimbaud, I., Pignon, P., Matsuzaki, J., Odunsi, K. O., Valmori, D., & Ayyoub, M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0579 · Cited by 160
Immunotherapy for Ovarian Cancer: What's Next?
Kandalaft, L. E., Powell, D. J., Singh, N., & Coukos, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2369 · Cited by 154
Muthuswamy, R., Berk, E., Junecko, B. A. F., Zeh, H. J., Zureikat, A. H., Normolle, D. P., Luong, T. M., Reinhart, T. A., Bartlett, D. L., & Kaliński, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4136 · Cited by 141
Lunardi, S., Jamieson, N. B., Lim, S. Y., Griffiths, K., Carvalho‐Gaspar, M., Al‐Assar, O., Yameen, S., Carter, R. C., McKay, C. J., Spoletini, G., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2519 · Cited by 135
Gorbachev, A. V., Kobayashi, H., Kudo, D., Tannenbaum, C. S., Finke, J. H., Shu, S., Farber, J. M., & Fairchild, R. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2278 · Cited by 126
Furuya, M., Suyama, T., Usui, H., Kasuya, Y., Nishiyama, M., Tanaka, N., Ishiwata, I., Nagai, Y., Shozu, M., & Kimura, S. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.03.023 · Cited by 109
Combination Strategies to Enhance Antitumor ADCC
Kohrt, H. E. K., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M. J., Levy, R., & Brody, J. (2012) · Immunotherapy · doi:10.2217/imt.12.38 · Cited by 103
Schmalfeldt, B., Kühn, W. M., Reuning, U., et al. (1995) · PubMed · Cited by 95
Self-citationHIGH EXPRESSION OF CHEMOKINE GENE AS A FAVORABLE PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA
Kondo, T., ITO, F., Nakazawa, H., Horita, S., Osaka, Y., & Toma, H. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000127726.25609.87 · Cited by 89
Möbus, V. J., Gerharz, C. D., Press, U., et al. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520115 · Cited by 87
Cycloxygenase-2 Inhibition Augments the Efficacy of a Cancer Vaccine
Haas, A. R., Sun, J., Vachani, A., Wallace, A. F., Silverberg, M. B., Kapoor, V., & Albelda, S. Μ. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1178 · Cited by 82
Tymoszuk, P., Charoentong, P., Hackl, H., Seeboeck, R., Müller‐Holzner, E., Trajanoski, Z., Obrist, P., Révillion-Carette, F., Peyrat, J., Fiegl, H., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-257 · Cited by 81
Suyama, T., Furuya, M., Nishiyama, M., Kasuya, Y., Kimura, S., Ichikawa, T., Ueda, T., Nikaido, T., Itô, H., & Ishikura, H. (2004) · Cancer · doi:10.1002/cncr.20747 · Cited by 80
Bronger, H., Kraeft, S., Schwarz‐Boeger, U., Cerny, C., Stöckel, A., Avril, S., Kiechle, M. B., & Schmitt, M. (2012) · Breast Cancer Research · doi:10.1186/bcr3115 · Cited by 78
Self-citationTargeted in vivo expression of IFN-γ-inducible protein 10 induces specific antitumor activity
Yang, X., Chu, Y., Wang, Y., Zhang, R., & Xiong, S. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306212 · Cited by 71
Cyclooxygenase inhibitors modulate NK activities that control metastatic disease
Kundu, N., Walser, T. C., Ma, X., & Fulton, A. M. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0669-2 · Cited by 68
Cyclooxygenase 2 Inhibition Promotes IFN-γ-Dependent Enhancement of Antitumor Responses
Sharma, S. P., Zhu, L. X., Yang, S.-C., Zhang, L., Lin, J. F.-H., Hillinger, S., Gardner, B. K., Reckamp, K. L., Strieter, R. M., Huang, M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.2.813 · Cited by 68
Markosyan, N., Chen, E. P., Evans, R. A., Ndong, V. N., Vonderheide, R. H., & Smyth, E. M. (2013) · Breast Cancer Research · doi:10.1186/bcr3469 · Cited by 63
Mariya, T., Hirohashi, Y., Torigoe, T., Asano, T., Kuroda, T., Yasuda, K., Mizuuchi, M., Sonoda, T., Saito, T., & Sato, N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0101 · Cited by 61
Tumor necrosis factor expression by human ovarian carcinoma in vivo.
Takeyama, H., Wakamiya, N., O’Hara, C., et al. (1991) · PubMed · Cited by 58
Tumor Infiltrating Lymphocytes in Ovarian Cancer
Gasparri, M. L., Attar, R., Palaia, I., Perniola, G., Marchetti, C., Donato, V. D., Farooqı, A. A., Papadia, A., & Panici, P. B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.9.3635 · Cited by 57
The Next Challenge in Cancer Immunotherapy: Controlling T-Cell Traffic to the Tumor
Abastado, J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3538 · Cited by 55
Specht, K., Harbeck, N., Smida, J., Annecke, K., Reich, U., Naehrig, J., Langer, R., Mages, J., Busch, R. M., Kruse, E., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0207-y · Cited by 46
Self-citationReyners, A. K. L., de Munck, L., Erdkamp, F., Smit, W. M., Hoekman, K., Lalisang, R. I., de Graaf, H., Wymenga, A. N. M., Polée, M., Hollema, H., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds107 · Cited by 45
Liu, M., Matsumura, N., Mandai, M., Li, K., Yagi, H., Baba, T., Suzuki, A., Hamanishi, J., Fukuhara, K., & Konishi, I. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.187 · Cited by 37
Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms
Bellati, F., Napoletano, C., Gasparri, M. L., Ruscito, I., Marchetti, C., Pignata, S., Tomao, F., Panici, P. B., & Nuti, M. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.09.006 · Cited by 30
Loessner, D., Abou‐Ajram, C., Benge, A., et al. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.05.014 · Cited by 30
Müller, M. A., Opfer, J., Brunie, L., Volkhardt, L. A., Sinner, E., Boettiger, D. C., Bochen, A., Kessler, H., Gottschalk, K., & Reuning, U. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.05.020 · Cited by 26
Self-citationHsin, L., Kao, H., Chen, I., Tsang, N., Hsu, C., Liu, S.-C., Chang, Y., & Chang, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080052 · Cited by 26
Monoclonal antibodies therapies for ovarian cancer
Maggiore, U. L. R., Bellati, F., Ruscito, I., Gasparri, M. L., Alessandri, F., Venturini, P. L., & Ferrero, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.767328 · Cited by 25
Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies
Bellati, F., Napoletano, C., Ruscito, I., Visconti, V. V., Antonilli, M., Gasparri, M. L., Zizzari, I. G., Rahimi, H., Palaia, I., Rughetti, A., et al. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313040014 · Cited by 16
Cited by
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627
Chemokines and the immune response to cancer
Ozga, A. J., Chow, M. T., & Luster, A. D. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.012 · Cited by 830
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
Metadata
- Authors
- Bronger, H., Singer, J., Windmüller, C., Reuning, U., Zech, D., Delbridge, C., Dorn, J., Kiechle, M., Schmalfeldt, B., Schmitt, M., & Avril, S.
- Venue
- British Journal of Cancer
- Published
- 2016-08
- Volume
- 115
- Issue
- 5
- Pages
- 553-563
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2488042065
- Cited by
- 274
- References
- 54
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.